Infliximab (Remicade) performs better in all aspects than Humira (adalimumab) for severe recalcitrant Hidradentis Suppurativa using the Sartorius Scoring System
To compare the efficacy and safety of infliximab and adalimumab in the treatment of HS. Hidradenitis suppurativa (HS) is a chronic relapsing skin disease. Recent studies have shown promising results of anti-tumor necrosis factor-alpha treatment.
A retrospective study was performed to compare 2 cohorts of 10 adult patients suffering from severe, recalcitrant HS. In 2005, 10 patients were treated with infliximab intravenous (i.v.) (3 infusions of 5 mg/kg at weeks 0, 2, and 6). In 2009, 10 other patients were treated in the same hospital with adalimumab subcutaneous (s.c.) 40 mg every other week. Both cohorts were followed up for 1 year using identical evaluation methods [Sartorius score, quality of life index, reduction of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), patient and doctor global assessment, and duration of efficacy].
Nineteen patients completed the study. In both groups, the severity of the HS diminished. Infliximab performed better in all aspects. The average Sartorius score was reduced to 54% of baseline for the infliximab group and 66% of baseline for the adalimumab group.
Adalimumab s.c. 40 mg every other week is less effective than infliximab i.v. 5 mg/kg at weeks 0, 2, and 6.
HUMIRA is a prescription medicine used to reduce the signs and symptoms of moderate to severe hidradenitis suppurativa in adults. Humira is used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and and a chronic skin condition called hidradenitis suppurativa. It is also used to treat Crohn’s disease or ulcerative colitis, after other drugs have been tried without successful treatment of symptoms.
Infliximab (INN; trade names Remicade, Remsima, Inflectra)
Infliximab (INN; trade names Remicade, Remsima, Inflectra) is a chimeric monoclonal antibody biologic drug that works against tumour necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases. Infliximab was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. It is used off-label outside its FDA approval for Behçet’s disease and other conditions.
Case Study Diagnosis Treatment